A premium, judgment-free guide to the major forms of psychedelic-assisted therapy — what each is, who explores it, how the experience differs, and how to pursue it safely.
It depends on the condition, not the hype: ibogaine for opioid and stimulant dependence, psilocybin for depression and existential distress, ketamine for rapid, legal relief in the US, MDMA-assisted therapy for PTSD where available, 5-MeO-DMT as a brief reset, ayahuasca for ceremonial depth. We map the fit with you.
Each path affects a different person differently, and who explores it differs too. Below you can compare them at a glance, then talk with an advisor who can help you find the right fit — and pursue it with a rigorously vetted provider. This is education, not medical advice.
The most documented interruption of opioid & alcohol dependence — it can switch off physical withdrawal.
Explore Ibogaine →A short, intense experience used primarily for trauma — often paired with ibogaine to heal what's underneath.
Explore 5-MeO-DMT →The most-studied psychedelic for depression, anxiety and end-of-life distress.
Learn about Psilocybin →The one you can access legally in the U.S. today — for treatment-resistant depression.
Learn about Ketamine →Studied intensively for PTSD as a tool that lets people revisit trauma without being overwhelmed.
Learn about MDMA →An Amazonian brew taken in ceremony for trauma, depression and deep self-inquiry.
Learn about Ayahuasca →Long-acting and powerful, ibogaine is the most documented interruption of substance dependence — and it demands the most rigorous medical screening of any path here. It's also the reason we exist: to make sure the provider you choose runs it safely.
A quick orientation — the shape of each experience, what people most often explore it for, and its legal status. Education, not medical advice.
| Treatment | With us | The experience | Most explored for | Legal status |
|---|---|---|---|---|
| Ibogaine | Network | Long — one journey, ~24–36 hrs | Opioid & alcohol dependence | Supervised clinics abroad |
| 5-MeO-DMT | Network | Brief & intense — minutes | Trauma, depression, ego reset | Varies by country |
| Psilocybin | Educational | Several hours | Depression, anxiety, end-of-life | Decriminalized / legal in some places |
| Ketamine | Educational | ~45–90 min sessions | Treatment-resistant depression | Legal in U.S. clinics |
| MDMA | Educational | ~3–5 hours, therapy-assisted | PTSD | Investigational — not yet approved |
| Ayahuasca | Educational | A long night, ceremonial | Trauma, depression, self-inquiry | Legal in some countries |
Special-operations veterans reported major improvements in PTSD, depression and functioning after supervised ibogaine.
What the observational data and early trials do — and don't — yet show about addiction outcomes.
Phase-3 momentum: where psilocybin sits on the path to approval for depression and anxiety.
What's legal, what's approved, and what "decriminalized" really means, plainly explained.
A plain-English map of the modern psychedelic-therapy toolkit and who each path tends to suit.
How recent federal moves are shifting psychedelic research and access for veterans.
Curated collections that take you from first question to a confident, safe decision.
Start from zero — the plain-English primer on what these treatments are and aren't.
02How it works, what to expect, the safety picture, and how the treatment actually unfolds.
03The green flags, the red flags, and the exact questions to ask before you commit.
An advisor can help you understand which paths may suit your situation — and connect you to safe, rigorously vetted care. Confidential and client-first.
The six treatment guides, the supporting explainers and the head-to-head comparisons.
Ketamine and esketamine nationally; psilocybin in Oregon and Colorado under state programs. Ibogaine, MDMA, 5-MeO-DMT and ayahuasca are accessed abroad or in trials.
Psilocybin and MDMA have randomised trials; ibogaine has strong observational data for opioid dependence and an open-label veteran study for PTSD and TBI.
From a single afternoon (ketamine) to 5–10 days abroad (ibogaine) to multi-week courses (MDMA-assisted therapy).
Ketamine roughly $400–$800 per infusion; ibogaine programs at the clinics we work with $5,000–$15,000, where the $5,000 floor is a negotiated rate that assumes no detox is required and you are not currently using; psilocybin and 5-MeO-DMT retreats vary widely.
